Floatz logo

Rapamycin

Hutchinson-Gilford Progeria Syndrome

Bundang CHA HospitalPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hutchinson-Gilford Progeria Syndrome cohort.

Asset / SponsorPhaseRating
Progerinin
PRG Science & Technology Co., Ltd.
Phase 2B
Umbilical Cord Blood Cell Infusion
Bundang CHA Hospital
Phase 1/2CCC

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →